Alzheimer's Disease
Conditions
Interventions
Healthy Volunteers (Control Group):None
Alzheimer's Disease (AD Group):None
Sponsors
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Alzheimer's disease (AD group): 1) Age = 60 years; 2) Meets the diagnostic criteria for AD (A+B): A: Specific clinical phenotype: Present with early and significant episodic memory impairment, including the following features: a. The patient or the informant reports memory decline that has persisted for more than 6 months and has progressively worsened; b. Objective evidence of hippocampal type amnestic syndrome, based on AD-specific detection methods, showing a significant decline in episodic memory ability; B: Evidence of AD pathological changes in the body (satisfying any one of the following): a. Decrease in Aß1–42 levels in cerebrospinal fluid and increase in T-tau or P-tau protein levels; b. Increased tracer retention in amyloid PET imaging; c. Presence of autosomal dominant mutations in AD (often carrying mutations in PSEN1, PSEN2, or APP); 3) Clinical Dementia Scale (CDR) = 0.5 points; 4) Agrees to participate and can cooperate with the study, and signs the informed consent form. 2.Mild Cognitive Impairment (MCI Group): 1)Age >= 60 years; 2) Impaired cognitive function, with MMSE score between 24 and 26; 3)Subjective cognitive complaints reported by the individual or an informant; 4)Generally normal activities of daily living, capable of performing daily tasks independently (e.g., ADLs); 5)Mild cognitive impairment confirmed by neuropsychological assessment; 6)Willing to participate, able to comply with the study, and provide written informed consent. 3.Healthy Volunteers (Control Group): 1) Age >= 60 years; 2) Normal cognitive function, with MMSE score >= 27; 3) No subjective complaints or objective symptoms of cognitive impairment; 4) No history of neurological diseases (e.g., stroke, traumatic brain injury, Parkinson's disease); 5) No history of psychiatric disorders (e.g., depression, anxiety), confirmed by professional assessment; 6) No severe systemic diseases (e.g., heart disease, liver disease, kidney disease) that may affect cognitive function; 7) Willing to participate, able to comply with the study, and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Alzheimer's disease (AD group): 1) Dementia or cognitive dysfunction caused by other diseases; 2) Complicated with delirium; 3) History of drug abuse; 4) Previous severe traumatic brain injury; 5) Complicated with depression, schizophrenia, Parkinson's disease; 6) Severe hearing loss, aphasia, etc. which affect the scale scores; 7) Complicated with serious diseases such as malignant tumors. 2.Mild Cognitive Impairment (MCI group): 1) Meets the clinical diagnostic criteria for dementia (such as Alzheimer's disease, vascular dementia, etc.); 2) Uses drugs that affect cognitive function (such as antidepressants, antipsychotics, etc.); 3) Has other major physical diseases: such as severe immune disorders, malignant tumors, etc. 3.Healthy volunteers (control group): 1) Have brain organic lesions; 2) Have other major physical diseases: such as severe immune disorders, malignant tumors, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma protein markers (differentially expressed proteins: screened by proteomics); | — |
Countries
China
Contacts
Public Contactkai zheng
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Outcome results
None listed